Business Context and Reporting Period
MiNK Therapeutics, Inc. (INKT) is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. This Form 10-Q covers the quarterly period ended June 30, 2025. The Company is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company. As of August 12, 2025, there were 4,522,927 shares of common stock outstanding.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(7,004,448) | $(6,515,101) |
| Net Loss Per Share (Basic & Diluted) | $(1.76) | $(1.82) |
| Operating Expenses | $6,753,083 | $6,900,995 |
| Cash and Cash Equivalents (End of Period) | $1,681,915 | $9,313,668 |
| Net Cash Used in Operating Activities | $(2,910,094) | $(4,832,887) |
| Total Current Liabilities | $13,163,565 | $6,959,676 |
| Accumulated Deficit | $(151,186,183) | $(139,912,034) |
Material Changes vs. Prior Period
- Liquidity Decline: Cash and cash equivalents decreased by approximately $2.9 million from $4.6 million at year-end 2024 to $1.7 million at June 30, 2025, driven by net cash used in operating activities.
- Expense Composition: Research and Development (R&D) expenses decreased 29% to $3.1 million for the six months ended June 30, 2025, compared to $4.4 million in the prior year, primarily due to decreased personnel costs and timing of clinical trials. Conversely, General and Administrative (G&A) expenses increased 33% to $3.1 million, driven by higher professional fees and incremental share-based compensation from an option award modification.
- Related Party Debt: A convertible promissory note with Agenus Inc. (a related party) was fully drawn in March 2024. As of June 30, 2025, the principal balance was $5.0 million with accrued interest of approximately $129,000. The fair value of this note was recorded at approximately $5.4 million, resulting in a non-cash expense of $532,012 for the six-month period.
- Stock Structure: A 1-for-10 reverse stock split was effected on January 28, 2025. All share and per-share data have been retroactively adjusted.
Outlook, Risks, and Unusual Items
- Going Concern Warning: The Company has disclosed substantial doubt about its ability to continue as a going concern for one year following the filing date due to an accumulated deficit of $151.2 million and reliance on future funding. Management believes current cash plus subsequent funding will satisfy requirements for more than one year.
- Subsequent Financing: In July 2025, the Company entered into an At Market Issuance Sales Agreement and sold approximately 478,000 shares, generating net proceeds of approximately $13.0 million.
- Controlled Company Status: Following the July 2025 stock sales, Agenus Inc.'s ownership dropped below 50%, and the Company no longer qualifies as a "Controlled Company" under Nasdaq rules, requiring a transition to full corporate governance compliance.
- Nasdaq Compliance: The Company received notice in May 2025 regarding non-compliance with the Minimum Value of Listed Securities (MVLS) rule but regained compliance by July 28, 2025.
- Clinical Progress: The Company is advancing its lead candidate, agenT-797, in Phase 2 trials for gastric cancer and viral ARDS. Preclinical data for engineered programs MiNK-215 and MiNK-413 continue to be generated.
Investor Verification Checklist
- Verify the status and terms of the $5.0 million convertible note with Agenus, including the conversion trigger and maturity date (January 1, 2026).
- Confirm the utilization of the $13.0 million raised in July 2025 and the remaining capacity under the $50.0 million At Market Issuance Sales Agreement.
- Monitor the Company's cash burn rate against the $1.7 million cash balance (pre-subsequent financing) to assess the runway for clinical trials.
- Review the impact of the loss of "Controlled Company" status on corporate governance and potential changes in board composition.
- Assess the timeline and funding requirements for the Phase 2 trials of agenT-797 in gastric cancer and viral ARDS.